Cargando…
Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa thera...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923424/ https://www.ncbi.nlm.nih.gov/pubmed/33672461 http://dx.doi.org/10.3390/diagnostics11020351 |
_version_ | 1783658899373555712 |
---|---|
author | Creta, Massimiliano Celentano, Giuseppe Napolitano, Luigi La Rocca, Roberto Capece, Marco Califano, Gianluigi Collà Ruvolo, Claudia Mangiapia, Francesco Morra, Simone Turco, Carmine Spirito, Lorenzo Fusco, Ferdinando Imbimbo, Ciro Mirone, Vincenzo Longo, Nicola |
author_facet | Creta, Massimiliano Celentano, Giuseppe Napolitano, Luigi La Rocca, Roberto Capece, Marco Califano, Gianluigi Collà Ruvolo, Claudia Mangiapia, Francesco Morra, Simone Turco, Carmine Spirito, Lorenzo Fusco, Ferdinando Imbimbo, Ciro Mirone, Vincenzo Longo, Nicola |
author_sort | Creta, Massimiliano |
collection | PubMed |
description | Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data. |
format | Online Article Text |
id | pubmed-7923424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79234242021-03-03 Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies Creta, Massimiliano Celentano, Giuseppe Napolitano, Luigi La Rocca, Roberto Capece, Marco Califano, Gianluigi Collà Ruvolo, Claudia Mangiapia, Francesco Morra, Simone Turco, Carmine Spirito, Lorenzo Fusco, Ferdinando Imbimbo, Ciro Mirone, Vincenzo Longo, Nicola Diagnostics (Basel) Review Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data. MDPI 2021-02-20 /pmc/articles/PMC7923424/ /pubmed/33672461 http://dx.doi.org/10.3390/diagnostics11020351 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Creta, Massimiliano Celentano, Giuseppe Napolitano, Luigi La Rocca, Roberto Capece, Marco Califano, Gianluigi Collà Ruvolo, Claudia Mangiapia, Francesco Morra, Simone Turco, Carmine Spirito, Lorenzo Fusco, Ferdinando Imbimbo, Ciro Mirone, Vincenzo Longo, Nicola Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title | Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title_full | Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title_fullStr | Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title_full_unstemmed | Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title_short | Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies |
title_sort | inhibition of androgen signalling improves the outcomes of therapies for bladder cancer: results from a systematic review of preclinical and clinical evidence and meta-analysis of clinical studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923424/ https://www.ncbi.nlm.nih.gov/pubmed/33672461 http://dx.doi.org/10.3390/diagnostics11020351 |
work_keys_str_mv | AT cretamassimiliano inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT celentanogiuseppe inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT napolitanoluigi inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT laroccaroberto inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT capecemarco inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT califanogianluigi inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT collaruvoloclaudia inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT mangiapiafrancesco inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT morrasimone inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT turcocarmine inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT spiritolorenzo inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT fuscoferdinando inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT imbimbociro inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT mironevincenzo inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies AT longonicola inhibitionofandrogensignallingimprovestheoutcomesoftherapiesforbladdercancerresultsfromasystematicreviewofpreclinicalandclinicalevidenceandmetaanalysisofclinicalstudies |